On February 16, 2021, Ozette, creators of a cutting edge artificial intelligence-powered Immune Monitoring Platform, announced $6 million in seed financing led by Madrona Venture Group, with participation from Allen Institute for Artificial Intelligence (AI2), and Vulcan Capital. Ozette, a collaboration between the Fred Hutchinson Cancer Research Center and AI2, will use the seed funding to accelerate breakthroughs in treating disease. Wilson Sonsini Goodrich & Rosati represented Ozette in the transaction.

Ozette’s Immune Monitoring Platform enables scientists to quickly extract reliable insights from single-cell data across instruments, experiments and disease states. Having this fully annotated data allows interpretable results for critical decision-making that will improve patient care and patient outcomes.

“Think of the Ozette Immune Monitoring Platform like an MRI for the immune system,” said Dr. Ali Ansary, co-founder and CEO of Ozette. “Where an MRI shows detailed images around the anatomical structures, our technology delivers a high-resolution view of the immune system at the single-cell level, providing details that haven’t been visible before. This makes treatments safer, faster to develop and personalized for patients.”

Wilson Sonsini advised Ozette on the financing. The team includes Craig Sherman, Myra Sutanto Shen, John Delaney, and Nabiila Hendryani-Soehedi.

For more information, please see Ozette's press release.